

ASX/Media Release

21/10/2020

## **Investor Webinar on Emyria entering into a global partnership with Sapphire Medical Clinics**

**Emyria Limited (ASX: EMD) (Emyria or the Company)**, a company that manages an Australia-wide clinical service for patients with unmet medical needs (Emerald Clinics) and also develops and commercialises clinical technologies and data products, is pleased to invite investors and shareholders to an online Investor Briefing. Chief Executive Officer, Michael Winlo will be providing an update to the market on the recently announced partnership with Sapphire Medical Clinics.

### **Details of the event are as follows:**

**Event:** Emyria Limited Investor Briefing

**Presenters:** Michael Winlo, Managing Director

**Time:** Thursday 22nd October 2020, 11.00 am (AEST)

**Where:** Zoom Webinar, details to be provided upon registration

To register your interest for the webinar, please click through to the link below:

[https://us02web.zoom.us/webinar/register/WN\\_WTo90yiZRtSLt1GBiX3RDA](https://us02web.zoom.us/webinar/register/WN_WTo90yiZRtSLt1GBiX3RDA)

Participants will be able to submit questions via the Panel throughout the webinar, however, given we are expecting a large number of attendees we encourage shareholders to send through questions via email beforehand to the Company via Investor and Media Relations manager Lexi O'Halloran at [lexi@janemorganmanagement.com.au](mailto:lexi@janemorganmanagement.com.au)

### **Highlights:**

- **Global partnership will leverage Sapphire's clinical and research expertise in the UK, and Emyria's real world evidence data expertise**
- **Emyria to receive select, deidentified data that will further improve Emyria's Registration and Pharmacovigilance data products**
- **Sapphire to become preferred clinical service of Emyria's clinical operations for patients in the UK**

### **For further information:**

Dr Michael Winlo  
CEO  
(08) 6559 2800  
[investors@emyria.com](mailto:investors@emyria.com)

Lexi O'Halloran  
Investor and Media relations  
+61 (0) 404 577 076  
[lexi@janemorganmanagement.com.au](mailto:lexi@janemorganmanagement.com.au)



#### **About Emyria ([www.emyria.com](http://www.emyria.com))**

Emyria Limited creates data products from robust and ethically sourced Real-World Evidence (RWE) gathered across its specialist clinical network - **Emerald Clinics ([www.emeraldclinics.com.au](http://www.emeraldclinics.com.au))**. Emyria's data products – **Emyria Registration** and **Emyria Pharmacovigilance** - accelerate the development and registration of new and promising treatments for patients with unmet medical needs by providing unique, real-world insights into treatment safety, quality and efficacy. Emyria's data assets are also a source of unique IP for Emyria. In addition, Emyria creates remote patient monitoring technologies, data platforms and care models that further improve the quality of its RWE data assets and insights.

#### **About Sapphire ([www.sapphireclinics.com](http://www.sapphireclinics.com))**

Sapphire Medical Clinics is the first medical cannabis clinic registered by the CQC in the UK and offers consultations at Harley Street in London or via telemedicine to patients with a wide range of conditions including paediatric neurology, pain, psychiatry and dermatology. The clinical governance processes at Sapphire are supported by a team of reputable specialists from Imperial College London and King's College, an in-house clinical pharmacist and overseen by Medical Director Dr Michael Platt. Treatment at Sapphire is focused on providing patients with the best available personalised medical care delivered by world renowned specialists. As recommended by NHS England, Sapphire has established a UK patient registry for cannabis-based medicinal products, as part of its Real-World Evidence Platform, which captures essential data including efficacy metrics, adverse events and patient-reported outcome measures using validated methodologies.

#### **Cautionary Note on Forward-Looking Statements**

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

